Drug Information

Drug General Information
Drug ID
D0O1GS
Former ID
DNCL001582
Drug Name
Fulranumab
Drug Type
Monoclonal antibody
Indication Arthralgia; Back pain; Cancer pain [ICD9: 724.5, 338, 780, 140-229; ICD10:M25.5, M54, G89, R52] Phase 3 [525054]
Company
Johnson & Johnson Pharmaceutical Research & Development
Target and Pathway
Target(s) Tumor necrosis factor receptor superfamily member 16 Target Info Antagonist [543520]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
PI3K-Akt signaling pathway
Neurotrophin signaling pathway
Transcriptional misregulation in cancer
Pathway Interaction Database p75(NTR)-mediated signaling
Neurotrophic factor-mediated Trk receptor signaling
Reactome Axonal growth inhibition (RHOA activation)
NRAGE signals death through JNK
p75NTR negatively regulates cell cycle via SC1
Regulated proteolysis of p75NTR
NADE modulates death signalling
NRIF signals cell death from the nucleus
p75NTR recruits signalling complexes
NF-kB is activated and signals survival
Axonal growth stimulation
WikiPathways Spinal Cord Injury
BDNF signaling pathway
Signalling by NGF
References
Ref 525054ClinicalTrials.gov (NCT02336685) Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001. U.S. National Institutes of Health.
Ref 543520(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.